Reducing treatment burden in the era of CFTR modulators - Authors' reply
- PMID: 37321238
- DOI: 10.1016/S2213-2600(23)00224-2
Reducing treatment burden in the era of CFTR modulators - Authors' reply
Conflict of interest statement
AHG reports grants and contracts from the Cystic Fibrosis Foundation, Insmed, AbbVie, and 4D Molecular Therapeutics. NM-H reports grants from the Cystic Fibrosis Foundation, National Institutes for Health, and US Food and Drug Administration; consulting fees from Enterprise Therapeutics; and Data and Safety Monitoring Board membership for the National Institutes for Health. DPN reports grants from the Cystic Fibrosis Foundation and National Institutes for Health; consulting fees from BiomX, Clarametyx, Genentech, GlaxoSmithKline, Nabriva, Respirion, and Vertex Pharmaceuticals; and advisory board membership for the Cystic Fibrosis Foundation and Kither Biotechnology.
Comment on
-
Reducing treatment burden in the era of CFTR modulators.Lancet Respir Med. 2023 Sep;11(9):e78. doi: 10.1016/S2213-2600(23)00223-0. Epub 2023 Jun 12. Lancet Respir Med. 2023. PMID: 37321239 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
